ClinicalTrials.gg
TerminatedNCT06111014Updated Jan 21, 2026

Continuation Study for Latozinemab

A Phase 3 interventional study of Latozinemab in Neurodegenerative Diseases, sponsored by Alector Inc.. Terminated at 18 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Alector Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies in Neurodegenerative Diseases with a site in United States — 45 open to participants now, 58 under way, 4 of them phase 3. Neurodegenerative Diseases · United States.

Enrollment
103rd of 120
17 · median 63
Started
2023
with 18 others
Phase 3
22 of 176
none open now
Registered
144th of 176
by date

Among the 176 studies in Neurodegenerative Diseases with a site in United States, this one is the 103rd largest by enrollment of the 120 interventional ones that give a count, is one of 19 that started in 2023, is one of 22 in phase 3, and was the 144th registered.

Neurodegenerative Diseases

436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.

Browse Neurodegenerative Diseases studies →

Open to participants now

45 of the 176 studies in Neurodegenerative Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Neurodegenerative Diseases with a site in United States, or all of them as a file.
02

Study summary

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Read the detailed description

This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.

All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).

03

Conditions studied

  • Neurodegenerative Diseases

Keywords

  • Frontotemporal Dementia (FTD)
  • Amyotrophic Lateral Sclerosis (ALS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
  • Has successfully completed participation in their parent latozinemab study.
  • Female participants must be nonpregnant and nonlactating.
  • Male participants must agree to acceptable use.

Exclusion criteria

Exclusion Criteria:

  • Known history of severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins.
  • heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Open Label

    Latozinemab (AL001) administered by IV infusion over 60 minutes, q4w

    Drug: Latozinemab

Interventions

  • All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks

    Also known as: AL001

06

What researchers measure

Primary outcomes

  1. Number of participants receiving latozinemab

    Number of participants receiving latozinemab

    Time frame: Through study completion, up to 190 weeks

  2. Duration of treatment with latozinemab

    Duration of treatment with latozinemab

    Time frame: Through study completion, up to 190 weeks

Secondary outcomes

  1. Incident of adverse events (AEs) and serious adverse events (SAEs)

    Number and percentage of participants of AEs or SAEs

    Time frame: Through study completion, up to 190 weeks

  2. Nature and severity of AEs and SAEs

    Severity of AEs and SAEs according to the World Health Organization (WHO) toxicity grading scale

    Time frame: Through study completion, up to 190 weeks

  3. Incidence of ADAs to latozinemab

    Number and percentage of participants with anti-Drug Antibodies (ADA) titer over study time points

    Time frame: Through study completion, up to 190 weeks

07

Study locations

18 sites
  • Dignity Health - Arizona
    Phoenix, Arizona 85013, United States
  • Mayo Comprehensive Cancer Center - PPDS
    Rochester, Minnesota 55905, United States
  • Irving Institute for Clinical and Translational Research
    New York, New York 10032, United States
  • University of Cincinnati Gardner Neuroscience Institute
    Cincinnati, Ohio 45219, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UZ Leuven
    Leuven, 3000, Belgium
  • Parkwood Institute
    London, Ontario N6C 0A7, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Groupe Hospitalier Pitié Salpétrière
    Paris, 75013, France
  • Universitätsklinikum Ulm - Leimgrubenweg 12-14
    Ulm, 89075, Germany
  • IRCCS - Centro S. Giovanni di Dio Fatebenefratelli
    Brescia, 25125, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico -Via Fracesco Sforza 35
    Milan, 20122, Italy
  • Azienda Ospedaliero Universitaria Di Modena Policlinico
    Modena, 41126, Italy
  • Erasmus MC-Dr. Molewaterplein 40
    Rotterdam, 3015 GD, Netherlands
  • Centro Hospitalar E Universitario de Coimbra EPE
    Coimbra, 3000-075, Portugal
  • Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
    Lisbon, 1649-028, Portugal
  • Karolinska Universitetssjukhuset Huddinge
    Huddinge, SE-14186, Sweden
  • University College London
    London, WC1NAR, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Sep 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Nov 1, 2023
StartActual
Dec 8, 2023
Primary completionActual
Sep 1, 2025
CompletionActual
Jan 7, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111014
Lead sponsor
Alector Inc.
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Dec 8, 2023
Primary completion
Sep 1, 2025
Completion
Jan 7, 2026
Last update
Jan 21, 2026

Study contacts

Study Lead
study director · Alector Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Latozinemab

Start the discussion